FLT4 and cancer: While blocking antibodies against VEGFR-3 are currently tested as anti-angiogenic and anti-metastatic drugs [15], the potential for antagonists of adenosine receptors to inhibit lymphangiogenesis and its deleterious consequences on tumor development and anti-cancer therapies has not been addressed.